Bristol-Myers Squibb Company (BMY)

64.68 +0.24 (+0.37%)
Closed USD Disclaimer
64.82 +0.14 (+0.22%)

Bristol-Myers Squibb Company Company Profile

Equity Type
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
Contact Information
New York,10016 United States
212 546 4000
Top Executives
Giovanni Caforio 57 2011 Chairman of the Board & CEO
Christopher S. Boerner 52 2018 Executive VP, COO & Director
Derica W. Rice 58 2020 Independent Director
Theodore Rapp Samuels 68 2017 Lead Independent Director
Peter J. Arduini 58 2016 Independent Director
Karen H. Vousden 65 2018 Independent Director
Deepak L. Bhatt 55 2022 Independent Director
Phyllis R. Yale 66 2019 Independent Director
Manuel Hidalgo Medina 55 2021 Independent Director
Julia A. Haller 68 2019 Independent Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.